Open AccessSalicylate decreases production of AmpC type β‐lactamases and increases susceptibility to β‐lactams in a Morganella morganii clinical isolate
Author(s) -
Tavío María M.,
Perilli Mariagrazia,
Vila Jordi,
Becerro Pino,
Casañas Lucía,
Amicosante Gianfranco,
Teresa Jiménez de Anta María
Publication year - 2004
Publication title -
fems microbiology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 151
eISSN - 1574-6968
pISSN - 0378-1097
DOI - 10.1111/j.1574-6968.2004.tb09748.x
Subject(s) - morganella morganii , nalidixic acid , microbiology and biotechnology , norfloxacin , complementation , chemistry , tetracycline , inducer , biology , antibiotics , mutant , enterobacteriaceae , biochemistry , escherichia coli , gene , ciprofloxacin
The effect of salicylate, a marRAB inducer, on the resistance to β‐lactams was characterized in an AmpC β‐lactamase hyperproducer Morganella morganii clinical isolate (the M1 strain). Results were compared with those of the effect of salicylate in a wild‐type M. morganii strain. Salicylate induced a decreased susceptibility to nalidixic acid, norfloxacin and tetracycline and simultaneously increased the susceptibility to β‐lactams apparently due to the repression of AmpC β‐lactamase synthesis in the M1 strain. Likewise, salicylate only repressed 46 kDa outer membrane protein expression in the wild‐type strain, since the clinical isolate M1 did not express it.